BackIonis Pharmaceuticals Overview
Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Target Price

Where could IONS trade next? Consensus target price: $93.

Get informed when a big investor buys or sells

+ Follow

Share Price

$60.36

Average Target Price

$93.4254.8% upside

12 analysts in the last 4 months

High: $130 | Low: $69

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-30H.C. WainwrightMitchell Kapoor$11590.5% upsideOpen
2026-07-29Goldman Sachs$6914.3% upsideOpen
2026-07-21GuggenheimDebjit Chattopadhyay$8947.4% upsideOpen
2026-07-13RBC CapitalLuca Issi$8540.8% upsideOpen
2026-07-10Morgan Stanley$11082.2% upsideOpen
2026-07-10Canaccord GenuityGary Nachman$9557.4% upsideOpen
2026-07-10BarclaysEliana Merle$9049.1% upsideOpen
2026-07-09Jefferies$9049.1% upsideOpen
2026-07-09NeedhamJoseph Stringer$8642.5% upsideOpen
2026-07-09Raymond James$8744.1% upsideOpen
2026-06-25H.C. Wainwright$130115.4% upsideOpen
2026-06-24Goldman Sachs$7524.3% upsideOpen
2026-04-30Oppenheimer$11183.9% upsideOpen
2026-04-30H.C. Wainwright$125107.1% upsideOpen
2026-04-30BarclaysEliana Merle$11590.5% upsideOpen
2026-04-21Morgan Stanley$130115.4% upsideOpen
2026-04-20Canaccord Genuity$11082.2% upsideOpen
2026-04-10Raymond JamesTiago Fauth$10472.3% upsideOpen
2026-02-25Morgan StanleyMichael Ulz$9557.4% upsideOpen
2026-02-25Needham$10370.6% upsideOpen
2026-02-06Piper Sandler$8744.1% upsideOpen
2026-01-05Wells Fargo$10065.7% upsideOpen
2025-12-17RBC CapitalLuca Issi$9557.4% upsideOpen
2025-12-15Leerink Partners$10065.7% upsideOpen
2025-11-04Piper Sandler$7727.6% upsideOpen
2025-10-30H.C. Wainwright$10065.7% upsideOpen
2025-10-30Morgan Stanley$9455.7% upsideOpen
2025-10-30Cowen & Co.$9964% upsideOpen
2025-10-30Barclays$9557.4% upsideOpen
2025-10-16Morgan Stanley$9049.1% upsideOpen
2025-10-08OppenheimerJustin Kim$9049.1% upsideOpen
2025-10-06Stifel Nicolaus$6711% upsideOpen
2025-09-26Goldman Sachs$657.7% upsideOpen
2025-09-23BarclaysGena Wang$8235.9% upsideOpen
2025-09-22Raymond JamesGary Nachman$7524.3% upsideOpen
2025-09-04RBC Capital$8032.5% upsideOpen
2025-09-03BMO CapitalKostas Biliouris$7016% upsideOpen
2025-09-02BarclaysGena Wang$7829.2% upsideOpen
2025-09-02Morgan StanleyMichael Ulz$7117.6% upsideOpen
2025-09-02Jefferies$9659% upsideOpen
2025-09-02H.C. WainwrightMitchell Kapoor$9557.4% upsideOpen
2025-08-22H.C. Wainwright$7016% upsideOpen
2025-08-22Wells FargoYanan Zhu$8235.9% upsideOpen
2025-08-22Barclays$583.9% downsideOpen
2025-08-21Stifel Nicolaus$4328.8% downsideOpen
2025-07-31H.C. Wainwright$657.7% upsideOpen
2025-07-30Morgan Stanley$622.7% upsideOpen
2024-10-09GuggenheimDebjit Chattopadhyay$657.7% upsideOpen
2024-08-02BMO CapitalKostas Biliouris$600.6% downsideOpen
2024-07-24Leerink PartnersMani Foroohar$622.7% upsideOpen

Ionis Pharmaceuticals (IONS) FAQ

Ionis Pharmaceuticals's target price stands at $93. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $93 for IONS implies 54.8% upside versus today's price ($60.36). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Ionis Pharmaceuticals's target price evolved across reporting periods, while the comparison chart places IONS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Ionis Pharmaceuticals's reading of $93 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.